In a statement Novartis AG said, it has launched a new share buyback of up to $15 billion which will end by 2023.

Confirming an expected sales growth by 4% through 2026, the Swiss pharma giant said its capital allocation strategy aims to combine investing in core business and returning excess capital to shareholders.

Categories: Creativity, Entrepreneurship, HR & Organization, Strategy

Tags: buyback, capital allocation strategy, core business, excess capital, forecast, growth, invest, investing, Novartis AG, pharma, sales, share, shareholders, Swiss